Metoclopramide
โ ๏ธ Key Safety Notes:
- Most common cause of drug-induced acute dystonia.
- Avoid in patients <21 years (especially young females).
- Contraindicated in bowel obstruction and Parkinsonโs disease.
- Restricted in the UK/EU to max 5 days use due to neurological risks.
๐ About
Always check the BNF link here.
- ๐ Dopamine antagonist anti-emetic with pro-kinetic action.
- โ ๏ธ Risk of acute dystonic reactions, especially in the young.
- Short-term use only (โค5 days) for nausea and vomiting.
โก Mechanism of Action
- โ Central D2 receptor blockade in the chemoreceptor trigger zone (CTZ).
- โฌ๏ธ Increases gastric emptying and enhances gut motility.
- โฌ๏ธ Reduces nausea and vomiting by blocking dopaminergic input to the vomiting centre.
๐ฉบ Indications
- ๐คข Nausea and vomiting (post-op, chemotherapy, palliative care).
- ๐ง Migraine (with analgesics, short-term use only).
- โก Gastroparesis or delayed gastric emptying (limited role, short-term).
- ๐ฅ As an adjunct with opioids to reduce opioid-induced gastric stasis.
๐ Dosing โ Metoclopramide (verify in BNF/datasheet)
| Drug / Indication |
Details |
| ๐ Metoclopramide |
โข Dose: 10 mg
โข Frequency: Up to TDS (every 8 h PRN)
โข Route: PO / IV / IM
|
- ๐ Maximum course: 5 days (safety restriction).
- ๐ IV: give slowly over โฅ3 minutes (rapid injection โ risk of dystonia/arrhythmia).
- โ๏ธ Reduce dose in renal impairment and elderly.
๐ซ Contraindications
- Age <21 years (high risk of dystonia, esp. females).
- Bowel obstruction or perforation.
- Parkinsonโs disease (worsens motor symptoms).
- Phaeochromocytoma (can trigger hypertensive crisis).
- Epilepsy (lowers seizure threshold).
- History of neuroleptic malignant syndrome (NMS).
๐ Interactions
- โฌ๏ธ Antagonises levodopa and dopamine agonists (worsens Parkinsonโs symptoms).
- โฌ๏ธ CNS depression with opioids, alcohol, benzodiazepines.
- May โ ciclosp